Literature DB >> 32304835

Eosinophilic granulomatosis with polyangiitis evolution during severe eosinophilic asthma treatment with benralizumab.

Alojzija Hočevar1, Peter Kopač2, Žiga Rotar1, Martina Plešivčnik Novljan1, Sabina Škrgat3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32304835     DOI： 10.1016/j.jaip.2020.04.006

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


× No keyword cloud information.
  3 in total

1.  New-onset eosinophilic granulomatosis with polyangiitis in 2 patients during treatment with IL-5 pathway inhibitors.

Authors:  Jan Holubar; Erik Arnaud; Jonathan Broner; Yves-Marie Pers; Alain Proust; Radjiv Goulabchand
Journal:  Immunol Res       Date:  2022-09-20       Impact factor: 4.505

Review 2.  Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis.

Authors:  Yasuhiko Koga; Haruka Aoki-Saito; Yosuke Kamide; Makiko Sato; Hiroaki Tsurumaki; Masakiyo Yatomi; Tamotsu Ishizuka; Takeshi Hisada
Journal:  Front Pharmacol       Date:  2022-03-10       Impact factor: 5.810

3.  Severe Asthma Where Eosinophilic Granulomatosis with Polyangiitis Became Apparent after the Discontinuation of Dupilumab.

Authors:  Miki Ikeda; Nobuharu Ohshima; Masahiro Kawashima; Meiko Shiina; Masashi Kitani; Maho Suzukawa
Journal:  Intern Med       Date:  2021-08-13       Impact factor: 1.271
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.